Prospective randomized controlled trial Comparing Peg-IFN alpha-2a monotherapy versus Peg-IFN alpha-2a +ribavirin combination therapy after curative ablation for HCV-positive Hepatocellular Carcinoma.

Trial Profile

Prospective randomized controlled trial Comparing Peg-IFN alpha-2a monotherapy versus Peg-IFN alpha-2a +ribavirin combination therapy after curative ablation for HCV-positive Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 May 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 23 Jan 2015 Planned End Date changed from 1 May 2016 to 31 May 2016 as reported by University Hospital Medical Information Network - Japan.
    • 11 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top